台灣泌尿科醫學會E-School

台灣泌尿科醫學會E-School

(TSA-2) 生技醫療產官學研合作之趨勢與政策應用面_翁紹仁院長

2023-10-13 • 觀看: 2 • 回應: 0 • 影片
(TSA-1) 健康政策改革藍圖、打造全人照護體系_石崇良署長

2023-10-13 • 觀看: 4 • 回應: 0 • 影片
(LS2-2) Selecting patients for PARP inhibitors in treatment of mCRPC_Axel S. Merseburger

2023-10-12 • 觀看: 24 • 回應: 0 • 影片
(LS2-1) Treatment intensification patterns and utilization in mCSPC_Axel S. Merseburger

2023-10-12 • 觀看: 10 • 回應: 0 • 影片
(ISTUA-4) 【Special lecture: Japan】Genetic polymorphism in pharmacotherapy for urological cancer_Prof. Masaki Shiota

2023-10-12 • 觀看: 2 • 回應: 0 • 影片
(ISTUA-3) 【Special lecture: Taiwan】 The prediction of clinically significant prostate cancer using urine metabolomic profiles determined by artificial intelligence_陳忠信

2023-10-12 • 觀看: 4 • 回應: 0 • 影片
(ISTUA-2) 【Special lecture: Japan】Application of AI in predicting the prognosis of prostate cancer_Prof. Shinichi Sakamoto

2023-10-12 • 觀看: 4 • 回應: 0 • 影片
(ISTUA-1) 【Special lecture: Taiwan】New strategies to conquer drug resistance in urothelial carcinoma_黃國皓

2023-10-12 • 觀看: 8 • 回應: 0 • 影片
(IS6-1) Review of clinical studies of PRP for ererctile dysfunction and peyronie’s disease treatment_姜宜妮

2023-10-12 • 觀看: 13 • 回應: 0 • 影片
(IS5-1) Transform the standard of care in 1L advanced or metastatic urothelial carcinoma_魏子鈞

2023-10-12 • 觀看: 13 • 回應: 0 • 影片
(IS4-1) New technology and current innovation in RIRS / Case study_陳鴻毅

2023-10-12 • 觀看: 14 • 回應: 0 • 影片
(IS3-1) The rapidly evolving landscape of first-line therapy in locally advanced or metastatic urothelial cancer_Terence W. Friedlander

2023-10-12 • 觀看: 18 • 回應: 0 • 影片

Prev
184
185
186
187
188
189
190
191
192
193
Next
/ 1056